Clinical Trial Search

Primary: Number of Participants Experiencing Adverse Events — 6; 7; 12 Participants

Primary: Adverse Events (AEs) Affecting Ocular Function That Differ Clinically From Those Expected in the Normal Course of Progression of XLRS — 3; 3; 12; 6 events

Primary: Rate of LOSS of 31 Hertz Cone Electroretinographic Function — 0.028; 0.022 log microvolts/year — p=0.30

Primary: Number of Participants Meeting the Primary Outcome Defined as Any of the Below Events Occurring During the 9 Weeks Following Administration, at Least Possibly Related to…

Primary: Part 1: Number of Participants With Dose-Limiting Toxicities (DLTs) — 0; 0; 0; 0 Participants

Primary: Number of Subjects With Serious Adverse Events — 0; 0 Participants

Primary: Overall Safety of Adeno-Associated Virus Vector (AAV-OPTIRPE65) - Number of Participants With a Safety Event — 0; 0; 1; 0 Participants

Primary: Proportion of Patients by Type of IRD — 720; 174; 30; 58 Participants

Primary: Systemic and Ocular Safety — 0; 0; 1; 0 Participants

Primary: Mean Change in Cone Spacing in Arcminutes (Z Score) of 2 Baseline Values Were Compared With Measurements Obtained at Post-op Month 36 — 1.13; 0.85 Difference in change…

Primary: Change in the Percentage of White Matter Hyperintensity (WMH) Lesion Volume on FLAIR MRI in RVCL Patients — 31.3 Percent (%)

Primary: Height (Amplitude) of Multifocal ERG Signal — 2.859 nanovolt/degree^2 — p=<0.05

Primary: Visual Acuity — 16.8; 14.5; 19.1; 15.3 letters on ETDRS Visual Acuity Chart

Primary: Safety (Participants With Ocular and Non-ocular AEs (Adverse Events) and SAEs (Serious Adverse Events)) — 6; 6; 6; 12 Participants

Primary: Mean Best-Corrected Visual Acuity (BCVA) as Measured by the Early Treatment of Diabetic Retinopathy Study (ETDRS) Chart in Letters at Month 12 — 68.0; 76.5; 82.3; 81.2…

Primary: Number of Participants Experiencing Ocular or Non-ocular Adverse Events — 6; 6 participants

Primary: Best Corrected Visual Acuity (BCVA) — 3.9; 1.3; 2.6 Letters correct — p=0.582

Primary: Number of Participants With Any Grade 3 or Greater Adverse Event (AE) Considered Related to AGN-151597 — 0; 0; 0; 0 participants

Primary: Adverse Event (AE) Reporting — 3; 3; 3; 2 Participants

Primary: Number of Subjects With Adverse Events as a Measure of Safety and Tolerability — 25; 21; 1 Participants

Primary: Change in Dark Adaptation Rod Intercept Time (RIT) From Baseline in the Study Eye at the Treatment Completion Visit (Month 2 for Cohort 1 and Month 1 for Cohort 2)…

Primary: Rate of Retinal Attachment — 50; 42 Participants

Primary: Rod Sensitivity Within the Central Retina as Measured on the Nidek MP-3S — 7; 20 Participants — p=<0.05

Primary: Proportion of Subjects With BCVA Gain of 15 or More Letters From Baseline in the Study Eye — 1; 1; 1 Participants

Primary: Number of Participants Meeting the Primary Outcome Defined as Any of the Below Events Occurring During the 6 Weeks Following Administration, at Least Possibly Related to…

Primary: The Number of Patients With no Fluid on OCT — 10 participants

Primary: Number of Participants Who Had Positive Genetic Test Results — 4 Participants

Primary: Mean Change in Best Corrected Visual Acuity (BCVA) at Month 12 Compared to Baseline — 12.3 Letters

Primary: Number of Participants Meeting the Primary Outcome Defined as Any of the Below Events Occurring During the 6 Weeks Following Administration, at Least Possibly Related to…

Primary: Frequency and Severity of Ocular Adverse Events in the Treatment and Contralateral Eyes — 6; 5 Participants